Identifying DNA markers to predict treatment outcomes in multiple myeloma
Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma
This study is looking at how certain changes in your DNA found in your blood can help doctors predict how well your multiple myeloma treatment will work, so they can tailor your care to better suit your needs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10430121 on NIH RePORTER |
What this research studies
This research investigates how specific changes in DNA, known as epigenomic markers, found in the blood of patients with multiple myeloma can help predict treatment outcomes. By analyzing circulating cell-free DNA, the study aims to identify markers that indicate a higher risk of early relapse after treatment. This non-invasive approach could provide valuable insights at the time of diagnosis, allowing for more personalized treatment plans. The research focuses on understanding the role of different DNA modifications in the progression of multiple myeloma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma who are beginning treatment.
Not a fit: Patients who are not diagnosed with multiple myeloma or those who have already experienced multiple relapses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prediction of treatment responses and improved management strategies for patients with multiple myeloma.
How similar studies have performed: Previous research has shown promise in using epigenetic markers for cancer prognosis, suggesting that this approach could be effective.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Chiu, Brian C-H — University of Chicago
- Study coordinator: Chiu, Brian C-H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.